Biosimulation Market worth $9.18 billion by 2029
The report "Biosimulation Market by Offering (Module, Integrated Platform), Application (Disease Modeling, PBPK, PKPD, Trial Simulation, Manufacturing & Supply chain: planning & forecasting), Indication (Cancer, CNS, CVS), End User, & Region - Global Forecast to 2029", is projected to reach USD 9.18 billion by 2029 from USD 4.24 billion in 2024, at a CAGR of 16.7% from 2024 to 2029.
Browse 153 market data Tables and 54 Figures spread through 350 Pages and in-depth TOC on "Biosimulation Market by Offering (Module, Integrated Platform), Application (Disease Modeling, PBPK, PKPD, Trial Simulation, Manufacturing & Supply chain: planning & forecasting), Indication (Cancer, CNS, CVS), End User, & Region - Global Forecast to 2029"
View detailed Table of Content here - https://www.marketsandmarkets.com/Market-Reports/biosimulation-market-838.html
The demand for biosimulation market is mainly driven by the growing need for low-cost drug development solutions, need to curtail high healthcare expenses, increasing biological system complexity that calls for advanced modeling approaches, and the need for personalized medicine based on individual patient data. Technological advancements in AI and High-Performance Computing (HPC) improve the precision and speed of the biosimulation models. The adoption of biosimulation is further encouraged by the rise in chronic disease prevalence worldwide as well as the integration of biosimulation tools in regulatory processes.
Molecular modeling & simulation software segment accounted for the largest share of the biosimulation market in 2023, by standalone modules
Molecular modeling & simulation software accounted for the largest market share in the biosimulation market in 2023, by standalone modules, due to its pivotal role in the critical drug discovery and development process. This software enables researchers and pharmaceutical companies to simulate interactions between molecules and predict the behavior of drugs at the molecular level, thus reducing the need for complicated, time-consuming, and costly experiments in laboratories. Through the simulation of intricate biological systems, it expedites the process of recognizing potential drug candidates, enhances lead selection procedures, and diminishes the probability of failure in subsequent phases of development.
The neurological disorders therapeutic area is poised to witness significant growth over the forecast period.
Neurological disorders segment is expected to witness a significant growth in the biosimulation market due to increasing prevalence of conditions such as Alzheimer's, Parkinson's, and multiple sclerosis among others. The Parkinson's Foundation reports that more than 10 million people worldwide suffer from Parkinson's Disease. Additionally, the World Health Organization (WHO) reports that more than 55 million people currently have dementia worldwide. These statistics illustrate the broad impact and rapid growth of neurological disorders globally. The complex features within the central nervous system and the multifactorial nature of these diseases require advanced modeling techniques to explain the mechanisms and foretell the outcome of any treatment. Moreover, the urge to deliver personalized medicine in neurology emphasizes extremely accurate models that would account for the influence of genetics and environment as well as lifestyle, life events, and other factors impacting the progression of the diseases and responses of treatments. Such factors are likely to drive growth of the neurological disorders segment.
North America accounted for the largest share of the biosimulation market in 2023.
North America held the most significant market share in the biosimulation market in 2023. The region is home to a large number of pharmaceutical and biotechnology industries, where companies are very aggressive in their R&D activities and help catalyze innovation. A significant presence of top companies, academic institutions, and regulatory bodies like the FDA help create a pro-equational atmosphere for incorporating newer biosimulation technologies. North America, further has massive financial resources, access to advanced technologies, well-developed healthcare infrastructure along with a prime focus on precision medicine and customized therapies. The need for smooth drug development processes amid pressure to adopt data-driven decision-making processes is a perfect catalyst for the growth in North America. These factors together work towards wholesome growth in biosimulation applications, making North America one of the dominant share holder in the market.
Prominent players in the Biosimulation market include are Certara USA. (US), Simulations Plus. (US), Dassault Systèmes (France), Schrödinger, Inc. (US), Advanced Chemistry Development, Inc. (Canada), Chemical Computing Group ULC. (Canada), Rosa & Co. LLC. (US), Genedata AG (US), Physiomics Plc (United Kingdom), In Silico Biosciences. (US), Allucent. (US), OpenEye, Cadence Molecular Sciences. (US), Cellworks Group, Inc. (US), VeriSIM Life. (US), Netabolics SRL (Italy), Charnwood Discovery (United Kingdom), The MathWorks, Inc. (US), ANSYS, Inc (US), Instem Group of Companies (United Kingdom), Insilico Medicine (US), SCM – Software Chemistry & Materials (Netherlands), BioSymetrics, Inc. (Canada), Atomwise Inc. (US), insitro. US), and Clinithink. (US).
About MarketsandMarkets™
MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.
Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.
MarketsandMarkets’s flagship competitive intelligence and market research platform, "Knowledgestore" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.
Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA : 1-888-600-6441
[email protected]
- Triangulate with your Own Data
- Get Data as per your Format and Definition
- Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
- Any level of Personalization
- What are the Known and Unknown Adjacencies Impacting the Biosimulation Market
- What will your New Revenue Sources be?
- Who will be your Top Customer; what will make them switch?
- Defend your Market Share or Win Competitors
- Get a Scorecard for Target Partners
